Oncoinvent to present at B. Riley Securities’ 3rd Annual Oncology Conference

Organiser: B. Riley Securities

CEO, Jan Alfheim will be presenting Oncoinvent at the virtual B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday 18th of January 2023 at 19:00 CET (01:00 PM ET). For more info please see https://brileyoncology22.sequireevents.com/.


Date: 18 January 2023
Program: Program

Anders Månsson

Chief Executive Officer


Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.